AzaSite Plus: Phase III data

Top-line data from the double-blind, U.S. Phase III DOUBle trial in 907 patients with moderate to severe blepharitis showed that AzaSite Plus and DexaSite each missed the primary endpoint of complete resolution of all clinical signs

Read the full 360 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE